Disability and intimate partner violence: A cross-sectional study from Mwanza, Tanzania.


Journal

Disability and health journal
ISSN: 1876-7583
Titre abrégé: Disabil Health J
Pays: United States
ID NLM: 101306633

Informations de publication

Date de publication:
04 2023
Historique:
received: 30 06 2022
revised: 12 10 2022
accepted: 09 11 2022
medline: 5 4 2023
pubmed: 16 12 2022
entrez: 15 12 2022
Statut: ppublish

Résumé

Women with disabilities are at heightened risk of experiencing intimate partner violence [IPV], although the mechanisms through which disability acts as a risk factor for IPV are not clear. We analyzed cross-sectional data (n = 867) from Wave 3 of the MAISHA longitudinal study, conducted in Mwanza, Tanzania, to i) describe the levels of disability and IPV amongst women, and ii) to assess the association between level and type of disability and IPV experience. IPV was assessed using the WHO Multi-Country study instrument. Levels of disability (none, mild and severe) were categorized based on responses to the Washington Group Short Set questions. We fitted logistic regression models to determine the risk of experiencing each type of IPV according to disability level and type of disability. We found significant associations between mild and severe disability and different types of IPV. For example, in multivariate analyses controlling for socio-demographic variables, women reporting severe disability were significantly more likely to report physical and/or sexual IPV, sexual IPV. controlling behaviors, economic IPV, and severe IPV, whereas for mild disability compared to no disability, physical and/or sexual IPV, sexual IPV, and economic IPV were significantly more likely to be reported. Cognitive disability was a significant correlate of all forms of IPV apart from physical IPV. Our findings that specific types of disability and not others were associated with an elevated risk of IPV exposure indicate the need for nuanced measurement and analysis of the association between disability and IPV.

Sections du résumé

BACKGROUND
Women with disabilities are at heightened risk of experiencing intimate partner violence [IPV], although the mechanisms through which disability acts as a risk factor for IPV are not clear.
OBJECTIVE
We analyzed cross-sectional data (n = 867) from Wave 3 of the MAISHA longitudinal study, conducted in Mwanza, Tanzania, to i) describe the levels of disability and IPV amongst women, and ii) to assess the association between level and type of disability and IPV experience.
METHODS
IPV was assessed using the WHO Multi-Country study instrument. Levels of disability (none, mild and severe) were categorized based on responses to the Washington Group Short Set questions. We fitted logistic regression models to determine the risk of experiencing each type of IPV according to disability level and type of disability.
RESULTS
We found significant associations between mild and severe disability and different types of IPV. For example, in multivariate analyses controlling for socio-demographic variables, women reporting severe disability were significantly more likely to report physical and/or sexual IPV, sexual IPV. controlling behaviors, economic IPV, and severe IPV, whereas for mild disability compared to no disability, physical and/or sexual IPV, sexual IPV, and economic IPV were significantly more likely to be reported. Cognitive disability was a significant correlate of all forms of IPV apart from physical IPV.
CONCLUSIONS
Our findings that specific types of disability and not others were associated with an elevated risk of IPV exposure indicate the need for nuanced measurement and analysis of the association between disability and IPV.

Identifiants

pubmed: 36522283
pii: S1936-6574(22)00158-3
doi: 10.1016/j.dhjo.2022.101404
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101404

Subventions

Organisme : Medical Research Council
ID : MC_PC_MR/S008691/1
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest All the authors indicate that they hold no conflicts of interest in relation to this publication.

Auteurs

Sarah R Meyer (SR)

Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Elisabeth-Winterhalter-Weg 6, 81377, München, Germany.

Neema R Mosha (NR)

Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Elisabeth-Winterhalter-Weg 6, 81377, München, Germany; Mwanza Intervention Trials Unit, PO Box 11936, Mwanza, Tanzania.

Tom Shakespeare (T)

International Centre for Evidence in Disability, London School of Hygiene and Tropical Medicine, Keppel St, London, UK.

Hannah Kuper (H)

International Centre for Evidence in Disability, London School of Hygiene and Tropical Medicine, Keppel St, London, UK.

Grace Mtolela (G)

Mwanza Intervention Trials Unit, PO Box 11936, Mwanza, Tanzania.

Sheila Harvey (S)

Mwanza Intervention Trials Unit, PO Box 11936, Mwanza, Tanzania; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, UK.

Saidi Kapiga (S)

Mwanza Intervention Trials Unit, PO Box 11936, Mwanza, Tanzania; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London, UK.

Gerry Mshana (G)

Mwanza Intervention Trials Unit, PO Box 11936, Mwanza, Tanzania; National Institute for Medical Research, Mwanza, Tanzania.

Heidi Stöckl (H)

Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians-Universität München, Elisabeth-Winterhalter-Weg 6, 81377, München, Germany; Department of Global Health and Development, London School of Hygiene and Tropical Medicine, 15-17 Tavistock Place, London, UK. Electronic address: heidi.stoeckl@lshtm.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH